ALA
Arovella Therapeutics Limited
🇦🇺 ASX
📦 LOGISTICS
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 1435.55%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
11
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. The firm is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The firm's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The firm is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.
📈 Performance
Price History
+207.56%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.18
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in ALA
11
📊 Total Capital Earnings
$89K
🔃 Average investment frequency
39 weeks
💵 Average investment amount
$1,564
⏰ Last time a customer invested in ALA
8 days
ALA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
17%
100k - 150k
17%
50k - 100k
50%
Less than 50k
17%
👶 Age of investors
18 - 25
26 - 34
55%
35 - 90
45%
🙋 Legal gender of investors
Female
64%
Male
36%
Pearlers who invest in ALA also invest in...
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
18.86%
📊 Share price
$57.74 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.85%
📊 Share price
$100.90 AUD
⛳️ DIVERSIFIED
🇦🇺 AUSTRALIA
🧱 MATERIALS
💸 FINANCIALS
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.71%
📊 Share price
$66.50 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
VESG.AX was created on 2018-09-11 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Ethically Conscious International Shares Index ETF seeks to track the return of the FTSE Developed ex Australia Choice Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax
🙌 Performance (5Yr p.a)
14.08%
📊 Share price
$93.48 AUD
📈 HIGH PRICE GROWTH
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
12.86%
📊 Share price
$129.54 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
Want more shares? Try these...
Albion Resources Ltd. is focused on exploration for lead, zinc, gold, and nickel. The company is headquartered in Perth, Western Australia. The company went IPO on 2021-04-30. The firm's projects include Mongers Lake Project, Lennard Shelf Project and Leinster Project. The Lennard Shelf Project is located in the Mississippi Valley type zinc-lead province, the Lennard Shelf, approximately 30 kilometers (km) southeast of Fitzroy Crossing in the Kimberley, Western Australia. The Lennard Shelf Project includes three sub-projects, covering an expansive area of over 319 square kilometers (km2) and contains comparable geology to Pillara and the Cadjebut Trend. The Leinster Project is located over 30 km southeast of Leinster, covers an area of 42 km2. The Mongers Lake Project covers a portion of the Yalgoo-Singleton Greenstone Belt in the Murchison Province of Western Australia, located between Capricorn Metals’ Mt Gibson Gold Project and Silver Lakes’ Rothsay Gold Project.
📊 Share price
$0.05 AUD
⛏️ MINING
Alcidion Group Ltd. engages in the development and provision of healthcare software products marketed under the Miya, Patientrack, Smartpage and ExtraMed brands. The company is headquartered in Melbourne, Victoria. The company went IPO on 2011-06-24. The firm's principal activities include the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of selected healthcare software products from its strategic partners and the delivery of product implementation, product support and maintenance, systems integration, and data analysis services to healthcare customers in Australia, New Zealand, and the United Kingdom. Its product, Miya Precision, is a smart clinical solution based on a FHIR-event platform that facilitates multiple clinical and operational applications. The firm's other products include Smartpage, Patientrack, and Silverlink PCS. Smartpage is an advanced smartphone and Web-based system for hospital communication and task management, addressing the requirements of both clinical and non-clinical users.
🙌 Performance (5Yr p.a)
-14.63%
📊 Share price
$0.05 AUD
🩺 HEALTH CARE
